Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)

1d ago, source:

Elevation Oncology's flagship project, EO-3021, is a phase 1 study targeting Claudin-18.2 and has shown promising early ...

ELEV Elevation Oncology, Inc.

14d ago, source: Seeking Alpha

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.

Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024

14d ago, source: Yahoo Finance

BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat ...

Elevation Oncology Stock (NASDAQ:ELEV), Quotes and News Summary

1mon ago, source: Benzinga.com

Elevation Oncology, Inc. (NASDAQ: ELEV) shares raced higher Monday. The company announced program updates and upcoming 2024 milestones on Friday. Erica Kollmann Why RxSight Shares Are Trading ...

Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023

1mon ago, source: Yahoo Finance

Warning! GuruFocus has detected 3 Warning Signs with ELEV. On March 6, 2024, Elevation Oncology Inc (NASDAQ:ELEV) released its 8-K filing, detailing the company's financial results for the fourth ...

Promising Preclinical Data and Positive Phase 2 Results Bolster Buy Rating for Elevation Oncology

14d ago, source: Business Insider

Begin your TipRanks Premium journey today. Elevation Oncology (ELEV) Company Description: Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the ...

Elevation Oncology Inc ELEV

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024

15d ago, source: Stockhouse

BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...

Elevation Oncology Inc (ELEV)

18d ago, source: Investing

View the ELEV option chain and compare options of Elevation Oncology Inc stock. Analyze the various options available, including call options (the right to buy) and put options (the right to sell ...